Market Overview:
The global biologics and biosimilars market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologic drugs, and technological advancements in the field of biosimilars. The monoclonal antibodies segment is expected to account for the largest share of the global biologics and biosimilars market in 2018. This segment is also projected to grow at the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to factors such as increasing incidence of cancer, growing demand for targeted therapies, and technological advancements in monoclonal antibody production methods.
Product Definition:
A biologic is a drug or other therapeutic agent that is produced from living organisms. Biosimilars are similar to but not identical to an original (reference) biologic product, and are typically much less expensive. The use of biosimilars can help to contain the cost of health care.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules, which are manufactured by the human body. They are different from polyclonal antibodies as they bind to a single antigen and fight against cancerous cells. Monoclonal Antibodies (MABs) can be used in various therapeutic areas such as oncology, autoimmune diseases, neurology and diabetes mellitus.
Interferon:
Interferons are a class of therapeutic proteins that are produced in response to viral infections. Interferons belong to the group of cytokines, which induce various types of immune responses by modulating the function and activity of natural killer cells, macrophages, and T cells. These interferons also have antiviral properties but these can be exploited by viruses for infection purposes as well.
Application Insights:
On the basis of application, the global market has been segmented into tumor, diabetes, cardiovascular disease (CVD), hemophilia and other. Biologics and biosimilars for cancer treatment held the largest share in 2017 owing to increasing adoption of these products by hospitals and healthcare providers. Cancer is a major health concern globally due to its rising prevalence rates as well as incidence rates. According to WHO¢â‚¬â„¢s latest statistics published in 2018, over 12 million people are diagnosed with cancer every year worldwide while around 8.8 million people die due to this disease each year also taking into consideration other causes such as non-fatal injuries caused by it which amounts up to 1 death every 2 minutes globally or approximately 740 deaths per minute or one death every 3 seconds according to another study done by WHO which can be found at wwww1.who.int/cancer/research/en/.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical manufacturers and strong government support for R&D investments are some factors contributing to the largest share. In addition, increasing investment by private players is also expected to drive growth over the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions during the forecast period owing to rising healthcare expenditure and growing patient awareness levels regarding biosimilars in emerging countries such as China, India, South Korea & Japan. Moreover, supportive regulations that enable easy access for novel therapies are anticipated to boost revenue generation in this region over next seven years.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. The rise in chronic diseases has led to an increase in the demand for biologics and biosimilars as they are used to treat a wide range of chronic conditions such as cancer, rheumatoid arthritis, Crohn’s disease, etc.
- Technological advancements: The field of biotechnology is constantly evolving with new technological advancements being made every day. This has led to the development of better and more effective biologics and biosimilars which are able to treat a wider range of illnesses than ever before.
- Growing awareness about biologics and biosimilars: There is growing awareness about the benefits offered by biologic drugs and biosimilars among both patients and healthcare professionals alike. This has helped to boost demand for these medications in recent years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Biologics and Biosimilars Market Research Report
By Type
Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other
By Application
Tumor, Diabetes, Cardiovascular, Hemophilia, Other
By Companies
Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Biologics and Biosimilars Market Report Segments:
The global Biologics and Biosimilars market is segmented on the basis of:
Types
Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumor, Diabetes, Cardiovascular, Hemophilia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
Highlights of The Biologics and Biosimilars Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Other
- By Application:
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biologics and Biosimilars Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biologics and biosimilars are medicines that are derived from living organisms. Biologics are typically proteins, while biosimilars are typically small molecules.
Some of the key players operating in the biologics and biosimilars market are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee.
The biologics and biosimilars market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biologics and Biosimilars Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biologics and Biosimilars Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biologics and Biosimilars Market - Supply Chain
4.5. Global Biologics and Biosimilars Market Forecast
4.5.1. Biologics and Biosimilars Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biologics and Biosimilars Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biologics and Biosimilars Market Absolute $ Opportunity
5. Global Biologics and Biosimilars Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biologics and Biosimilars Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies
5.3.2. Interferon
5.3.3. Erythropoietin
5.3.4. Insulin
5.3.5. Vaccines
5.3.6. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biologics and Biosimilars Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biologics and Biosimilars Market Size and Volume Forecast by Application
6.3.1. Tumor
6.3.2. Diabetes
6.3.3. Cardiovascular
6.3.4. Hemophilia
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biologics and Biosimilars Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biologics and Biosimilars Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biologics and Biosimilars Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biologics and Biosimilars Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biologics and Biosimilars Demand Share Forecast, 2019-2026
9. North America Biologics and Biosimilars Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biologics and Biosimilars Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biologics and Biosimilars Market Size and Volume Forecast by Application
9.4.1. Tumor
9.4.2. Diabetes
9.4.3. Cardiovascular
9.4.4. Hemophilia
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biologics and Biosimilars Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies
9.7.2. Interferon
9.7.3. Erythropoietin
9.7.4. Insulin
9.7.5. Vaccines
9.7.6. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biologics and Biosimilars Demand Share Forecast, 2019-2026
10. Latin America Biologics and Biosimilars Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biologics and Biosimilars Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biologics and Biosimilars Market Size and Volume Forecast by Application
10.4.1. Tumor
10.4.2. Diabetes
10.4.3. Cardiovascular
10.4.4. Hemophilia
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biologics and Biosimilars Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies
10.7.2. Interferon
10.7.3. Erythropoietin
10.7.4. Insulin
10.7.5. Vaccines
10.7.6. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biologics and Biosimilars Demand Share Forecast, 2019-2026
11. Europe Biologics and Biosimilars Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biologics and Biosimilars Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biologics and Biosimilars Market Size and Volume Forecast by Application
11.4.1. Tumor
11.4.2. Diabetes
11.4.3. Cardiovascular
11.4.4. Hemophilia
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biologics and Biosimilars Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies
11.7.2. Interferon
11.7.3. Erythropoietin
11.7.4. Insulin
11.7.5. Vaccines
11.7.6. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biologics and Biosimilars Demand Share, 2019-2026
12. Asia Pacific Biologics and Biosimilars Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biologics and Biosimilars Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biologics and Biosimilars Market Size and Volume Forecast by Application
12.4.1. Tumor
12.4.2. Diabetes
12.4.3. Cardiovascular
12.4.4. Hemophilia
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biologics and Biosimilars Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies
12.7.2. Interferon
12.7.3. Erythropoietin
12.7.4. Insulin
12.7.5. Vaccines
12.7.6. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biologics and Biosimilars Demand Share, 2019-2026
13. Middle East & Africa Biologics and Biosimilars Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biologics and Biosimilars Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biologics and Biosimilars Market Size and Volume Forecast by Application
13.4.1. Tumor
13.4.2. Diabetes
13.4.3. Cardiovascular
13.4.4. Hemophilia
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biologics and Biosimilars Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies
13.7.2. Interferon
13.7.3. Erythropoietin
13.7.4. Insulin
13.7.5. Vaccines
13.7.6. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biologics and Biosimilars Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Biologics and Biosimilars Market: Market Share Analysis
14.2. Biologics and Biosimilars Distributors and Customers
14.3. Biologics and Biosimilars Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AbbVie
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi-Aventis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Johnson & Johnson
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novo Nordisk
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. 3sbio
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Changchun High Tech
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. CP Guojian
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Biotech
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Gelgen
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Innovent
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Dong Bao
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Ganlee
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
